Shyndec subsidiary gets approval for key diabetes drug ingredient

Shanghai Shyndec Pharmaceutical Co., Ltd. announced its wholly-owned subsidiary, Sinopharm Weiqida Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug, Sitagliptin Phosphate. This approval, effective October 11, 2025, allows for the domestic sale of the drug, a DPP-4 inhibitor primarily used for glycemic control in patients with type 2 diabetes.

The approved product has a registration number Y20230001220 and a registration standard YBY70142025, with a packaging specification of 20kg/barrel.

This development will enrich Shanghai Shyndec Pharmaceutical's specialized raw material drug portfolio, although it is not expected to significantly impact current operating performance. The total research and development investment for Sitagliptin Phosphate raw material by Sinopharm Weiqida has been approximately CNY 5.29 million. The company cautioned investors that sales of raw materials are subject to uncertainties from terminal preparation demand and market supply.